Delivery Order SPE2DB20D3103-SPE2DB26FL4V2
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Lacosamide 10 mg/ml solution in a 200ml quantity, with a contract ceiling value of $3,155.52. This award was made on November 3, 2025, with an ultimate completion date of November 4, 2025, under a firm fixed price delivery order with no set-aside designation. The contract represents a competitive award for pharmaceutical procurement to support federal medical supply needs, with performance...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Lacosamide 10 mg/ml Solution in a 200ml quantity, with a ceiling value of $2,681.84 and an ultimate completion date of August 20, 2025. This is a firm fixed price delivery order with no set-aside designation, issued under competitive procedures. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, the company's headquarters...
- AmerisourceBergen Drug Corp was awarded a delivery order on August 12, 2025, by the Defense Logistics Agency's Medical Supply Chain for the supply of Lacosamide 10 mg/ml solution in a 200 ml quantity, with a contract ceiling value of $1,051.54. This firm fixed-price delivery order represents a competitive award with no set-aside designation and is scheduled for ultimate completion by August 13, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency Troop Support Medical awarded a $176,940 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 200 milliliters of the pharmaceutical product lacosamide 10 mg/ml solution. The place of performance will be Amerisourcebergen's facility located in Conshohocken, Pennsylvania. The period of performance is July 31, 2023 through August 1, 2023. This delivery order was issued against an existing indefinite-delivery/indefinite-quantity contract vehicle held...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Lacosamide 200 mg/20 mL vials valued at $2,509.57. This is a firm fixed-price delivery order with an ultimate completion date of September 25, 2025, and represents no set-aside procurement. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Lacosamide 100 mg tablets in unit dose packaging (60-count), valued at $2,165.55. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 27, 2025. This delivery...
- The U.S. Department of Defense's Defense Logistics Agency (DLA) awarded a Delivery Order contract worth $1,177.78 to AmerisourceBergen Drug Corp's Corporate Office division. The contract is for the supply of Lacosamide 10 mg/ml solution in 200ml bottles. This Delivery Order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that AmerisourceBergen holds with DLA Troop Support Medical, which serves as the primary vehicle for the company to provide a wide range...
- The U.S. Defense Department's Medical Supply Chain awarded a $1,433.01 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Lacosamide 50 mg/5 mL unit dose vials. This competitively awarded, non-set-aside contract is scheduled for completion by September 18, 2025, with performance to be executed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child action under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4563830313 - Lacosamide 10 mg/ml solution 200 ml. The contract has a completion date of March 4, 2024 and a potential value of $1,450.26. Amerisourcebergen Drug Corp is the prime contractor and there is no set-aside designation for this award. The contract is part of a larger indefinite delivery contract (IDC) between...
- This is a $1,464.96 firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation for the supply of lacosamide 10 mg/ml solution in 200 ml bottles. The contract does not have a set-aside designation and has an ultimate completion date of September 13, 2024. AmerisourceBergen, a major pharmaceutical distributor, is providing these prescription drug products to support federal healthcare programs and facilities. The award is part of a larger...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB26FL4V2Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Lacosamide 10 mg/ml Solution 200ml, with a ceiling value of $1,002.66 under a firm fixed price contract structure. This competitively awarded delivery order, issued on November 3, 2025, with an ultimate completion date of November 4, 2025, represents a continuation of the vendor's ongoing pharmaceutical supply relationship with the federal government. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle extending through December 2026. As a prime pharmaceutical distributor for the military healthcare system, AmerisourceBergen supplies an extensive portfolio of medications and medical supplies across multiple therapeutic domains to support Defense Health Agency and other federal healthcare customers worldwide. The company's federal contracting history demonstrates consistent capability in delivering both specialty and generic pharmaceutical products through competitive procurement processes with no set-aside designation applied to this award.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.0k | 11/3/25 |